MS and Demyelinating Disorders

Neurology News Network for the week ending February 22, 2020.

New data suggest a switch from natalizumab to a high efficacy disease-modifying therapy for patients with multiple sclerosis is more beneficial than switching to moderate efficacy therapy, including a lower risk of disease activity.

The Prometra II offers a pressure-driven, valve-gated delivery mechanism that allows for novel programming modes of intermittent flow followed by periods of no flow—a feature unique to this device.

Neurology News Network for the week ending February 15, 2020.

Neurofilament light chain has emerged as a biomarker with utility across the breadth of neurology, but just how much can it actually help?